Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Maintenance therapy in MM: perspectives

Graham Jackson • 6 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Bortezomib Daratumumab Ixazomib Lenalidomide

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, outlines the perspectives on maintenance therapy in multiple myeloma (MM). Prof. Jackson highlights the use of lenalidomide, daratumumab and ixazomib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Graham Jackson

0:58
Education gaps in CAR-T therapy
Graham Jackson • 13 May 2022
0:58
The efficacy of ixazomib for the treatment of R/R myeloma
Graham Jackson • 13 May 2022
1:09
Treatment holidays in multiple myeloma
Graham Jackson • 13 May 2022
1:10
Infection prophylaxis in multiple myeloma
Graham Jackson • 13 May 2022

Related Videos

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals